Immunological Patient Stratification in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.
Rohrhofer, Johanna, Hauser, Lisa, Lettenmaier, Lisa et al. · Journal of clinical medicine · 2024 · DOI
Quick Summary
This study found that ME/CFS patients have different types of immune system problems. Researchers divided patients into two groups: those with weakened immune systems and those with normal immune systems. The two groups showed different patterns of illness—one group had low levels of a protective immune protein, while the other group had signs that their gut barrier was leaking. This suggests that ME/CFS may not be one disease but rather multiple conditions that need different treatment approaches.
Why It Matters
This research demonstrates that ME/CFS is not a single uniform disease but comprises at least two distinct biological subgroups with different immune and gut problems. Identifying these subgroups is crucial because different patients may need different treatments—a one-size-fits-all approach has likely failed because researchers and clinicians have been mixing together patients with fundamentally different underlying mechanisms.
Observed Findings
- ME/CFS patients with immunodeficiency showed significantly reduced serum C4a complement protein levels compared to other patients.
- ME/CFS patients without immunodeficiency demonstrated elevated lipopolysaccharide-binding protein (LBP) levels, indicating intestinal barrier leakage.
- Two immunologically distinct subgroups of ME/CFS patients exhibited different patterns of immune and gastrointestinal dysfunction.
- Serum inflammatory mediators and intestinal barrier biomarkers differed significantly between the stratified patient groups.
- Detailed medical record documentation revealed consistent associations between immune competence status and specific biomarker profiles.
Inferred Conclusions
- ME/CFS comprises at least two pathophysiologically distinct subgroups requiring different stratification approaches for research and clinical practice.
- Immunodeficient ME/CFS patients have selective innate immune dysregulation involving the complement pathway, while immunocompetent patients primarily manifest intestinal barrier dysfunction.
- Precise immunological stratification is essential for identifying suitable, personalized treatment strategies in ME/CFS.
- The heterogeneity of immune dysfunction in ME/CFS explains why previous undifferentiated treatment approaches have shown limited efficacy.
Remaining Questions
- Do the identified immune subgroups respond differently to specific treatments, and can this stratification predict treatment outcomes?
- What causes the intestinal barrier dysfunction in immunocompetent ME/CFS patients, and does healing the gut barrier improve overall symptoms?
- Are these two subgroups stable over time, or do patients shift between groups, and if so, what triggers such changes?
- How do these immunological patterns relate to post-exertional malaise and other core ME/CFS symptoms, and can biomarker changes predict PEM severity?
What This Study Does Not Prove
This study does not establish causation—it only shows associations between immune status and biomarkers at one point in time. It cannot prove that intestinal barrier dysfunction or complement deficiency causes ME/CFS, only that these differences exist in subgroups of patients. The relatively small sample size limits the generalizability of findings to all ME/CFS patients worldwide.
Topics
Tags
Metadata
- DOI
- 10.3390/jcm13010275
- PMID
- 38202282
- Review status
- Machine draft
- Evidence level
- Single-study or moderate support from human research
- Last updated
- 7 April 2026